Both TAT-Gap24-treated and TAT-Gap19-treated NASH mice exhibited decreased levels of triglycerides, cholesterol, IL-1β as well as higher quantities of SOD in liver tissue. The gene discussed is IL1B; the disease is metabolic dysfunction-associated steatohepatitis.